Bivalirudin

Therapeutic

For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.

Structural features

SMILES

CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O

Sequence

fPRPGGGGNGDFEEIPEEYL

Molar mass

2180.317 g/mol

Constitutional members:

20

Natural amino acids

19

D-Amino acids

1

N-terminus

H

C-terminus

COOH

Cyclic

no

Members/cycle

N.A.

Bond to form cycle

N.A.

Lipidation

no

Glycosylation

no

Route of administration

IV, IC

Terminal half-life

25 min (up to 3.5h for dyalisis-dependant patients)

Protein binding

Other than thrombin and red blood cells, bivalirudin does not bind to plasma proteins.

Absorption and Bioavailability

The bioavailability of bivalirudin for intravenous use is complete and immediate.

References